Sepsis Clinical Trial
Official title:
Can Respiratory Rate Predict the Risk of Deterioration of Septic Patients
Verified date | November 2018 |
Source | PMD Solutions |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
The primary objective is to determine if the trend in Respiratory Rate measurements provided
by the device under investigation can be used to predict an increase in
Sequential/Sepsis-related Organ Failure Assessment (SOFA) score.
The RR trend will be measured as the difference between the RR recorded by the device at a
point 15 minutes after commencement of treatment, as per the standard of care for patients
suspected of being septic, and a point 3 hours following this.
Status | Completed |
Enrollment | 132 |
Est. completion date | November 21, 2017 |
Est. primary completion date | September 9, 2017 |
Accepts healthy volunteers | |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria - = 18 Years - Admitted for a minimum of 12 hours - Have been diagnosed with sepsis Sepsis diagnosis confirmed by documented or suspected infection (ordering of blood culture or other microbiological investigation by the clinician) and =1 of the following presenting within the first 4 hours of admission: - Fever or hypothermia, Core temperature > 38.3 or < 36 °C - Heart rate > 90/min - Respiratory rate > 20/min - Altered consciousness/mental state, defined as GCS < 15 - Hyperglycemia, (BS > 6.7 mmol/L non-diabetic) - LKC > 12 *10^9 or < 4*10^9, - Normal LKC with > 10 % immature cells, - CRP > highest normal local lab. Interval - Hypotension: Systolic BP <90 mmHg, or drop in systolic BP > 40 - Hypoxemia: PaO2 < 8.5 Kpa or PaO2/FiO2 < 40 or tissue perfusion: P-lactate > 1.6 - Creatinine . 177 µmol/L - Acute oliguria (Diuresis per hour ,0.5 ml/kg/t or 45 ml/t in 2 hours) - Coagulopathy: Spontaneous INR > 1.5, or apt > 60 sec, thrombocytopenia - Paralytic ileus (absence of bowel sounds) - Hyperbilirubinemia > 34µmol/L - Are willing to voluntarily sign a statement of informed consent to participate in this investigation Exclusion criteria - Allergic to medical grade skin adhesive - Pregnant women during second and third trimester - Continuous long term steroid use. Defined as not using steroids in the 4 weeks previous to enrolment - Patients under the influence of substance abuse (drug or alcohol) that may interfere with their ability to cooperate and comply with the investigation procedures - Any disorder, including cognitive dysfunction, which would affect the ability to accurately complete questionnaires and freely give full informed consent. This will be determined by the Abbreviated Mental Test Score (AMT) Cannot be followed a second time if admitted again at a later date during the study period |
Country | Name | City | State |
---|---|---|---|
Denmark | Hospital of South West Jutland, Department of Emergency Medicine | Esbjerg | South West Jutland |
Lead Sponsor | Collaborator |
---|---|
PMD Solutions | Hospital of South West Jutland |
Denmark,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Upward trend in Respiratory Rate as a predictor of 30 day readmission. | The secondary endpoint is the 30 day readmission rate after discharge. | 30 days after discharge | |
Primary | RespiraSense triggered escalation in SOFA score | Escalation of SOFA score by 2 or more points. The primary endpoint will be evaluated with an ANCOVA with escalation of SOFA score by 2 or more points as a factor and mean RR in the first hour of treatment as a covariate. | 15 minutes after commencement of treatment, as per the standard of care for patients suspected of being septic, and a point 3 hours following this. | |
Secondary | Upward trend in Respiratory Rate as a predictor of 30 day mortality | The secondary endpoint is the 30 day mortality rate after discharge. | 30 days after discharge |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05095324 -
The Biomarker Prediction Model of Septic Risk in Infected Patients
|
||
Completed |
NCT02714595 -
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
|
Phase 3 | |
Completed |
NCT03644030 -
Phase Angle, Lean Body Mass Index and Tissue Edema and Immediate Outcome of Cardiac Surgery Patients
|
||
Completed |
NCT02867267 -
The Efficacy and Safety of Ta1 for Sepsis
|
Phase 3 | |
Completed |
NCT04804306 -
Sepsis Post Market Clinical Utility Simple Endpoint Study - HUMC
|
||
Recruiting |
NCT05578196 -
Fecal Microbial Transplantation in Critically Ill Patients With Severe Infections.
|
N/A | |
Terminated |
NCT04117568 -
The Role of Emergency Neutrophils and Glycans in Postoperative and Septic Patients
|
||
Completed |
NCT03550794 -
Thiamine as a Renal Protective Agent in Septic Shock
|
Phase 2 | |
Completed |
NCT04332861 -
Evaluation of Infection in Obstructing Urolithiasis
|
||
Completed |
NCT04227652 -
Control of Fever in Septic Patients
|
N/A | |
Enrolling by invitation |
NCT05052203 -
Researching the Effects of Sepsis on Quality Of Life, Vitality, Epigenome and Gene Expression During RecoverY From Sepsis
|
||
Terminated |
NCT03335124 -
The Effect of Vitamin C, Thiamine and Hydrocortisone on Clinical Course and Outcome in Patients With Severe Sepsis and Septic Shock
|
Phase 4 | |
Recruiting |
NCT04005001 -
Machine Learning Sepsis Alert Notification Using Clinical Data
|
Phase 2 | |
Completed |
NCT03258684 -
Hydrocortisone, Vitamin C, and Thiamine for the Treatment of Sepsis and Septic Shock
|
N/A | |
Recruiting |
NCT05217836 -
Iron Metabolism Disorders in Patients With Sepsis or Septic Shock.
|
||
Completed |
NCT05018546 -
Safety and Efficacy of Different Irrigation System in Retrograde Intrarenal Surgery
|
N/A | |
Completed |
NCT03295825 -
Heparin Binding Protein in Early Sepsis Diagnosis
|
N/A | |
Not yet recruiting |
NCT06045130 -
PUFAs in Preterm Infants
|
||
Not yet recruiting |
NCT05361135 -
18-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in S. Aureus Bacteraemia
|
N/A | |
Not yet recruiting |
NCT05443854 -
Impact of Aminoglycosides-based Antibiotics Combination and Protective Isolation on Outcomes in Critically-ill Neutropenic Patients With Sepsis: (Combination-Lock01)
|
Phase 3 |